Durable Interim Results, Essex Bio-Technology Drives Growth and Innovation

Secret Results Highlights:

– Income Growth: 5.8% boost to roughly HK$ 876.5 million.
– Net Profit Increase: 3.8% increase to HK$ 163.4 million, driven by functional effectiveness.
–Interim Dividend: Proposed at HK$ 0.07 cents per share, 16.7% rise, up from HK0.06 in 2024.
– Net Cash & & Cash Equivalents: HK$ 640.5 million (HK$ 557.2 million in 2024)

Regulative Milestones:

– NMPA Approval: Multi-dose Diquafosol Sodium Eye Drops authorized for registration and commercialization in the PRC.
– BLA Acceptance: Bevacizumab ophthalmic injection BLA accepted by NMPA, marking an essential regulative turning point.

Service Development:

– Cooperation with Seefunge: For the Group to specifically disperse Seefunge’s Emedastine Difumarate and Oxybuprocaine Hydrochloride Eye Drops.
– Collabration with Airdoc: For celebrations to collectively run Fundus AI service.

Copyright and Market Presence:

– Robust IP Portfolio: 111 patent certificates or authorisation letters, making up 81 creation patents, 15 energy design patents and 15 style patents.
– Wide Distribution Network: Products readily available in over 14,100 medical facilities and medical companies, and roughly 2,100 pharmaceutical shops throughout the PRC

Awards and Recognition:

– 2024 Top 100 Innovative Companies in Zhuhai: Recognised for development and quality
– 2024 Top 100 Companies with Economic Contributions in Zhuhai: Acknowledged for considerable financial effect

HONG KONG, Aug 26, 2025 – (ACN Newswire) –Essex Bio-Technology Limited (“Essex” and its subsidiary the “Group”, Stock Code: 1061. HK), a leading biologic Group that establishes, makes and commercialises genetically crafted restorative recombinant bovine fundamental fibroblast development element (“rb-bFGF”), today revealed its interim outcomes for the 6 months ended 30 June 2025 (“the duration under evaluation”).

In the very first half of 2025, the market continued to deal with obstacles from worldwide geopolitical unpredictabilities and progressing domestic centralised procurement characteristics. Helpful federal government policies cultivating development and structured drug approval procedures sped up compensation cycles.

Essex leveraged beneficial patterns and emerging chances, driving strong success development and broaden its market footprint. Our unrelenting concentrate on R&D development, tactical financial investments in flagship biologics, and broadened client gain access to in lower-tier cities in China added to durable functional efficiency. The continuous developments in its healthtech e-platform likewise supported our development momentum.

Our accomplishments highlight Essex’s steadfast commitment to development and functional quality, which drive continual momentum in both profits and revenue development.

Conditioning Financial Position and Shareholder Returns

Throughout the duration under evaluation, the Group’s earnings was mainly stemmed from its operations in the PRC and denominated in Renminbi. The Group attained a combined turnover of around HK$ 876.5 million, with a boost of 5.8% as compared to roughly HK$ 828.5 million for the exact same duration in 2015. The Group’s earnings increased by 3.8% to around HK$ 163.4 million as compared to roughly HK$ 157.4 million for the very same duration in 2015.

Since 30 June 2025, the Group had money and money equivalents of around HK$ 640.5 million (31 December 2024: roughly HK$ 557.2 million). The Group’s tailoring ratio stayed steady at 29.7% (31 December 2024: 28.8%), showing the Group’s sensible monetary management abilities and strong liquidity.

The Board is pleased to propose an interim dividend of HK$ 7.0 cents (for the 6 months ended 30 June 2024: HK$ 6.0 cents) per regular share for the 6 months ended 30 June 2025, highlighting the Group’s dedication to providing investor worth.

Diversified Growth Fueled by Flagship Biologics

The Group’s turnover is mainly comprised of Ophthalmology and Surgical (including injury care and recovery) and arrangement of services sections. For the 6 months ended 30 June 2025, Ophthalmology contributed roughly HK$ 417.4 million to the Group’s turnover, while Surgical taped an overall turnover of roughly HK$ 449.0 million, representing about 47.6% and 51.2% of the Group’s overall turnover, respectively. The core items that are present development motorists under each section are:

1. Ophthalmology– Beifushu ® series (Beifushu ® eye drops, Beifushu ® eye gel and Beifushu ® unit-dose eye drops), Tobramycin Eye Drops, Levofloxacin Eye Drops, Sodium Hyaluronate Eye Drops, Moxifloxacin Hydrochloride Eye Drops, Diquafosol Sodium Eye Drops, (Iodized Lecithin Capsules), Soft Hydrophilic Contact Lens and other medical gadgets for myopia control and avoidance such as eye-protection light and Seewant defocus personalized glasses;

2. Surgical (incorporating injury care and recovery)– Beifuji ® series (Beifuji ® spray, Beifuji ® lyophilised powder and Beifuxin ® gel), Carisolv ® cavities elimination gel,(Dr. YaDian) oral care items, (Yi Xue An Granules), Portable Ultraviolet Phototherapy Devices, PELNACTM collagen-based synthetic dermis, SCALGENTM double-layered synthetic dermis and Osteopore’s bioresorbable implants (Osteomesh ® and Osteoplug ®)for oral surgery in Singapore; and

3. Arrangement of services– Healthtech e-platform associated medical services.

Presently, the Group has 6 self-developed and manufactured commercialised biologics (jointly described as the “bFGF Series”) that are marketed and offered in the PRC, and 3 of them were authorized by NMPA as Category I biologics. The combined turnover of the bFGF Series represented about 83.5% of the Group’s overall turnover for the duration under evaluation. The Group has a portfolio of commercialised preservative-free unit-dose eye drops and 2 oral care items, as well as a variety of Ophthalmology and Surgical items and medical gadgets to match the Group’s rehabs service.

Strategic R&D Secures Market-Leading Milestones

The Group tactically purchases ingenious items and innovations to improve its R&D pipeline, devoted to unique treatments that satisfy crucial unmet medical and market needs. In the very first half of 2025, overall R&D expenses were roughly HK$ 66.5 million, representing 7.6% of the turnover, of which roughly HK$ 44.8 million were capitalised.

Throughout the duration, the Group acquired NMPA approval for the registration and commercialisation of the multi-dose Diquafosol Sodium Eye Drops in the PRC. The approval is anticipated to enhancing treatment choices for persistent dry eye clients and additional strengthening the Group’s leading position and total competitiveness in the ophthalmology sector.

The international stage 3 medical job of bevacizumab ophthalmic injection (EB12-20145P) has actually effectively finished the last check out for client registration throughout several areas consisting of the PRC, Australia, European Union nations and the United States. Significantly, NMPA accepted the Biologics License Application (BLA) for this ingenious treatment in August 2025, marking an important regulative turning point.

The Group holds an overall of 111 patent certificates or authorisation letters, consisting of 81 development patents, 15 energy design patents and 15 style patents.

The Group has numerous R&D websites situated in Zhuhai (PRC), Boston (USA), London (UK) and Singapore, assisting in the advancement of ingenious rehabs and the destination of global skill.

To date, the Group has 18 R&D programs varying from pre-clinical to medical phases, with 4 ophthalmology programs presently in late scientific phase, particularly Bevacizumab intravitreal injection, SkQ1 eye drops, Azithromycin eye drops, and Cyclosporine eye drops, which are targeted at being mid-term development chauffeurs.

Market Expansion and Operational Enhancements

As at 30 June 2025, the Group preserves a comprehensive network of 46 local sales workplaces in the PRC. With a large circulation network, the Group’s items are recommended in more than 14,100 healthcare facilities and medical service providers, in addition to roughly 2,100 pharmaceutical shops, covering significant cities throughout the PRC. The Group’s Singapore base has actually been getting excellent advancement traction given that 2020.

In company advancement, the Group participated in a tactical cooperation with Airdoc to collectively run fundus AI organization. In addition, the Group has actually participated in a special circulation arrangement with Seefunge for the Seefunge’s Emedastine Difumarate and Oxybuprocaine Hydrochloride Eye Drops. Emedastine Fumarate Eye Drops is mainly utilized for dealing with allergic conjunctivitis in grownups and kids aged 3 years and above while Oxybuprocaine Hydrochloride Eye Drops is mostly utilized for corneal surface area anesthesia. The brand-new additions will even more improve the Group’s ophthalmic item portfolio and enhance its market placing in ophthalmology.

To sustain development and broaden its item portfolio, the Group has actually been actively boosting competitiveness and market reach by expanding medical signs of commercialised items, increasing client gain access to in lower-tier cities throughout the PRC, establishing complementary sales channels, and advancing its healthtech e-platform to additional enhance client ease of access.

The Group’s 2nd factory at Zhuhai Hi-Tech Industrial Park, covering roughly 58,000 square meters for R&D, production, workplace and dorm, is anticipated to finish in the duration of 2026-2027.

Mr. Patrick Ngiam, Chairman of Essex Bio-Technologyspecified, “Our innovation-driven technique, sustained by functional quality, a strong monetary structure, and a growing market existence, positions us for sustainable development and international growth. We stay dedicated to enhancing client results and producing long-lasting worth for investors.”

About Essex (1061. HK)

Essex is a bio-pharmaceutical business that establishes, produces, and commercialises genetically crafted healing b-bFGF, with 6 commercialised biologics presently marketed in China. In addition, the Company has a varied portfolio of commercialised preservative-free unit-dose eye drops, Shilishun (Iodized Lecithin Capsules) and others, which are mainly recommended for injury recovery and illness in Ophthalmology and Dermatology.

These items are marketed and offered through roughly 14,100 health centers, supported by the Company’s 46 local workplaces in China. Leveraging its internal R&D platform in development element and antibody innovation, Essex preserves a robust pipeline of jobs in different medical phases, covering a large range of fields and indicators.

Site: http://www.essexbio.com

Subject: Press release summary